$2.55 Billion is the total value of NEA Management Company, LLC's 30 reported holdings in Q1 2012. The portfolio turnover from Q4 2011 to Q1 2012 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2012 | ||||||||
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2012-05-04
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLYCOMIMETICS INC | 41 | Q1 2024 | 7.6% |
| AURINIA PHARMACEUTICALS INC | 40 | Q2 2024 | 5.0% |
| CHAMPIONS ONCOLOGY INC | 36 | Q2 2024 | 1.2% |
| LEXICON PHARMACEUTICALS INC | 35 | Q2 2024 | 2.0% |
| ADAPTIMMUNE THERAPEUTICS PLC | 34 | Q2 2024 | 9.3% |
| CRISPR THERAPEUTICS AG | 31 | Q2 2024 | 11.2% |
| TREVENA INC | 31 | Q3 2021 | 3.3% |
| AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
| ARDELYX INC | 29 | Q3 2021 | 11.9% |
| VERONA PHARMA PLC | 29 | Q2 2024 | 9.0% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.